DENVER, Colo., Nov 06, 2024 (247marketnews.com)- Sonnet BioTherapeutics (NASDAQ: SONN) stated that the United States Patent and Trademark Office (USPTO) issued U.S. Patent# 12,134,635 entitled “Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same,” covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB).
Pankaj Mohan, Ph.D., Sonnet’s CEO and Founder, stated, “The issuance of this intellectual property is an important milestone that we believe provides significant differentiation from competitors trying to tap the full biological potential of IL-18, either alone or in combination with IL-12. IL-18 is a key cytokine that, when combined synergistically with IL-12, has the potential to be an important therapeutic asset for oncology and cell-based therapy.”
The post Sonnet BioTherapeutics Issued USTPO Patent Covering Two Novel Immunotherapeutic Drug Candidates appeared first on 24/7 MarketNews.